GSK and Daiichi Sankyo eye leading vaccines position in Japan via new JV
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline and Daiichi Sankyo have now confirmed that they will set up a vaccines joint venture in Japan to handle existing and future products from both partners, following local media leaks of a tie-up ahead of the formal announcement.